Small Molecules to Improve Myelination in Alzheimer's Disease and APOE4 Carriers
The present disclosure provides methods of inhibiting amyloid synthesis in a subject using cyclodextrin and analogs thereof. Small molecules (cyclodextrin) reverse APOE4-associated cholesterol phenotypes and lead to significantly improved myelination both human in vitro cultures and APOE4 targeted replacement mice. This demonstrates that APOE4 alters cholesterol synthesis and transport in oligodendrocytes which impairs myelination. Collectively, this work uncovers a pathogenic role of APOE4 in oligodendrocytes and myelination and enables therapeutic opportunities for Alzheimer's Disease.
Researchers
-
apoe4 impairs myelination via altered cholesterol biosynthesis and transport in neuronal cells
Patent Cooperation Treaty | Published application -
apoe4 impairs myelination via altered cholesterol biosynthesis and transport in neuronal cells
United States of America | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.